MGMT Promoter Methylation and Parathyroid Carcinoma

CONTEXT: Parathyroid carcinoma (PC) is extremely rare. Prognosis is poor, with no known evidence-based systemic therapies. We previously reported complete remission in a patient with metastasized parathyroid carcinoma and high tumor MGMT promoter methylation status who was treated with temozolomide....

Descripción completa

Detalles Bibliográficos
Autores principales: Storvall, Sara, Ryhänen, Eeva, Heiskanen, Ilkka, Vesterinen, Tiina, Bensch, Frank V, Schildt, Jukka, Kytölä, Soili, Karhu, Auli, Arola, Johanna, Schalin-Jäntti, Camilla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Clinical Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821197/
https://www.ncbi.nlm.nih.gov/pubmed/31687638
http://dx.doi.org/10.1210/js.2019-00175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821197/
https://www.ncbi.nlm.nih.gov/pubmed/31687638
http://dx.doi.org/10.1210/js.2019-00175

Ejemplares similares